阿利西尤单抗治疗未增加神经认知不良事件:14项随机对照试验个体数据Meta分析
该研究汇总14项阿利西尤单抗2/3期随机对照试验的个体患者数据,比较神经认知治疗中出现的不良事件(TEAE)发生率。阿利西尤单抗组与安慰剂或依折麦布组相比,神经认知TEAE发生率低且无显著差异,LDL-C<25 mg/dL者与≥25 mg/dL者发生率相似。
要点
- 阿利西尤单抗组神经认知TEAE发生率≤1.2%,与安慰剂或依折麦布无显著差异。
- LDL-C<25 mg/dL与≥25 mg/dL患者神经认知TEAE发生率相似。
- 因神经认知TEAE停药者罕见,阿利西尤单抗组与对照组相近。
核心结论
- 阿利西尤单抗治疗患者神经认知TEAE发生率低(≤1.2%),与对照相比无显著差异,最长随访104周。
- 基于已完成的2/3期试验,未发现神经认知TEAE与LDL-C<25 mg/dL相关,但PCSK9抑制剂诱导的极低LDL-C长期影响尚不明确。
研究设计与样本
- 汇总14项阿利西尤单抗2期和3期随机对照试验的个体患者数据。
- 患者多数接受最大耐受剂量他汀背景治疗,随机接受阿利西尤单抗75/150 mg每2周(n=3340,4029患者年暴露)、安慰剂(n=1276)或依折麦布(n=618)。
主要发现
- 安慰剂对照试验中,阿利西尤单抗组神经认知TEAE报告22例(0.9%),安慰剂组9例(0.7%),HR 1.24(95%CI 0.57-2.68)。
- 依折麦布对照试验中,阿利西尤单抗组10例(1.2%),依折麦布组8例(1.3%),HR 0.81(95%CI 0.32-2.08)。
- LDL-C<25 mg/dL(<0.65 mmol/L)者神经认知TEAE 5/839例(0.6%,0.5/100患者年),LDL-C≥25 mg/dL者26/2501例(1.0%,0.8/100患者年)。
- 因神经认知TEAE导致停药:阿利西尤单抗组1例(0.1%,依折麦布对照池),安慰剂组2例(0.2%),依折麦布组3例(0.4%)。
- 按年龄分层后,阿利西尤单抗组与对照组神经认知TEAE发生率仍相似。
临床怎么用
- 对于接受阿利西尤单抗治疗的患者,神经认知不良事件风险低,无需因担忧认知副作用而常规回避治疗。
- 将LDL-C降至25 mg/dL以下时,现有2/3期试验数据未显示神经认知TEAE增加,但长期影响仍需监测。
局限性
- PCSK9抑制剂诱导的极低LDL-C水平长期效应目前未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Despite patient reports of neurocognitive disorders with lipid-lowering treatments (LLTs), large clinical trials have found no significant association between neurocognitive disorders and LLTs. We assessed incidence of neurocognitive treatment-emergent adverse events (TEAEs) from 14 Phase 2 and 3 trials of the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab. METHODS AND RESULTS: Patients (most on background maximally tolerated statin) received alirocumab 75/150 mg every 2 weeks (n = 3340; 4029 patient-years of exposure), placebo (n = 1276), or ezetimibe (n = 618). Data were pooled by the control used. Neurocognitive TEAEs were reported by 22 (0.9%) alirocumab-treated patients vs. 9 (0.7%) with placebo in placebo-controlled trials [hazard ratio (HR) 1.24, 95% confidence interval (CI) 0.57-2.68] and 10 (1.2%) with alirocumab vs. 8 (1.3%) with ezetimibe in ezetimibe-controlled trials (HR 0.81, 95% CI 0.32-2.08). Rates of neurocognitive TEAEs were similar in patients receiving alirocumab with LDL cholesterol (LDL-C) levels <25 mg/dL (<0.65 mmol/L; n = 5/839; 0.6%; 0.5/100 patient-years) vs. ≥25 mg/dL (n = 26/2501; 1.0%; 0.8/100 patient-years). One patient (0.1%; ezetimibe-controlled pool) receiving alirocumab had a neurocognitive TEAE leading to discontinuation vs. two (0.2%) patients receiving placebo and three (0.4%) patients receiving ezetimibe. Neurocognitive TEAE incidence was also similar between alirocumab and controls when stratified by age. CONCLUSIONS: Neurocognitive TEAE incidences were low (≤1.2%), with no significant differences between alirocumab vs. controls up to 104 weeks. No association was found between neurocognitive TEAEs and LDL-C <25 mg/dL based on the completed Phase 2 and 3 trials examined, although long-term effects of very low LDL-C levels induced by PCSK9 inhibitors are currently unknown.
引用
- Harvey PD, Sabbagh MN, Harrison JE, et al. No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur Heart J. 2018. PMID: 29186504. doi:10.1093/eurheartj/ehx661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。